Sangamo Therapeutics Reports on Pfizer's Announcement of ...

Giroctocogene fitelparvovec is a novel, investigational gene therapy that contains a bio-engineered AAV6 capsid and a modified B-domain deleted human ...

Sangamo Therapeutics Reports on Pfizer's Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate ... By clicking “ ...

Sangamo Therapeutics Reports on Pfizer's Announcement of ...

Pfizer Inc.'s announcement of positive topline results from the Phase 3 AFFINE trial (NCT04370054) evaluating giroctocogene fitelparvovec.

Sangamo Therapeutics Reports Recent Business Highlights and ...

Reported Pfizer's announcement of positive topline results from ... therapy that Sangamo is co-developing with and licensing to Pfizer.

Pfizer Announces Positive Topline Results From Phase 3 Study of ...

(NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study (NCT04370054 ) evaluating giroctocogene fitelparvovec, an ...

Sangamo Therapeutics Reports on Pfizer's Announcement of ...

Giroctocogene fitelparvovec is a novel, investigational gene therapy that contains a bio-engineered AAV6 capsid and a modified B-domain deleted human ...

Sangamo Therapeutics Reports on Pfizer's Announcement of ...

Sangamo Therapeutics Reports on Pfizer's Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate.

News Releases | Investor Relations - Sangamo Therapeutics, Inc.

RICHMOND, Calif. --(BUSINESS WIRE)--Nov. 4, 2024-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the ...

Sangamo Therapeutics Reports Recent Business Highlights and ...

Pfizer plans to present detailed data from Phase 3 AFFINE trial evaluating giroctocogene fitelparvovec, an investigational Hemophilia A gene ...

Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of ...

New York, NY, and Brisbane, California, September 22, 2022 - Pfizer and Sangamo Therapeutics announced that the Phase 3 AFFINE study ...

StockWatch: Phase III Data for Pfizer-Partnered Hemophilia A Gene ...

Sangamo stock soared this week after it joined Pfizer to report positive Phase III data for their hemophilia A gene therapy candidate.

Sangamo Therapeutics Reports Recent Business Highlights and ...

Pivotal readout expected in mid-2024 in the Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy we are ...

Sangamo Therapeutics And Pfizer Announce That SB-525 ...

Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European ...

Sangamo Reports Pfizer's Positive Phase 3 Hemophilia A Gene ...

RICHMOND, Calif.--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomics-focused medical company, has announced that Pfizer Inc. shared ...

Pfizer Marks Phase III Success in Hemophilia A, then Layoffs after ...

Pfizer marked a success, and a setback, in its ongoing effort to develop gene therapies. The company joined Sangamo Therapeutics to report positive Phase III ...

Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB ...

Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor ...

Pfizer touts Phase 3 gene therapy data in hemophilia A, but now it ...

Pfizer announced Wednesday that its gene therapy for hemophilia A met the primary objective in a key clinical trial, and the company plans to bring the data to ...

Pfizer's Hemophilia A Trial Shows Superiority Over FVIII Prophylaxis

Sangamo Therapeutics Reports on Pfizer's Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate.

Sangamo Soars On Pfizer's Hemophilia A Gene Therapy Trial Results

Shares of Sangamo Therapeutics Inc. (SGMO), a genomic medicine company, were up over 70% in early trading today, following positive topline ...

Sangamo Therapeutics Reports Recent Business Highlights and ...

Pfizer plans to present detailed data from Phase 3 AFFINE trial evaluating giroctocogene fitelparvovec, an investigational Hemophilia A gene ...